Log in or Sign up for Free to view tailored content for your specialty!
Hidradenitis Suppurativa News
Orismilast may improve hidradenitis suppurativa with dose-dependent tolerability
Orismilast may improve mild to severe hidradenitis suppurativa; however, further studies are needed to confirm patient tolerability in this indication, according to a study.
Hidradenitis suppurativa improvement shown with lutikizumab
Phase 2 trial results found lutikizumab was efficacious in treating hidradenitis suppurativa in patients who had previously failed anti-tumor necrosis factor therapy, AbbVie announced in a press release.
Log in or Sign up for Free to view tailored content for your specialty!
Healio Minute Podcast, Dermatology Edition: Top Headlines - Week of December 18, 2023
In this edition, an advocacy group petitions the FDA for stronger safety warnings for Botox, melanoma regression is associated with improved prognosis and more.
Novel, oral RGRN-305 shows promise in hidradenitis suppurativa treatment
RGRN-305 inhibits heat shock protein 90, and this action may modulate inflammation from hidradenitis suppurativa, according to a study.
Cosentyx approval tops 2023 hidradenitis suppurativa news
The FDA’s approval of Cosentyx leads Healio Dermatology’s most read articles this year about hidradenitis suppurativa.
Tape strips may identify hidradenitis suppurativa in lesional, nonlesional skin
Tape strips show promise as a minimally invasive way to identify hidradenitis suppurativa and create individualized treatment plans for patients with this disease, according to a study.
Convolutional neural networks show promise in management of hidradenitis suppurativa
Convolutional neural networks may be able to detect hidradenitis suppurativa-affected skin and classify disease severity, according to a study.
Dermatologists, other clinicians differ in pediatric hidradenitis suppurativa treatment
Dermatologists are more likely to prescribe standard of care therapies to children with hidradenitis suppurativa compared with non-dermatologists, according to a study.
KT-474 reduces inflammation in patients with hidradenitis suppurativa, atopic dermatitis
Results from a phase 1 study show that KT-474 reduced disease-relevant inflammatory biomarkers in the blood and skin of patients with hidradenitis suppurativa or atopic dermatitis, according to a Kymera Therapeutics press release.
Healio Minute Podcast, Dermatology Edition: Top Headlines - Week of November 13, 2023
In this edition, dermatologists ‘uniquely positioned’ to aid human trafficking victims; FDA approves Cosentyx for hidradenitis suppurativa and more.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read